Palantir Co-Founder Joe Lonsdale on the AI Investment Boom

By Bloomberg Technology

Categories: Startup, VC, AI

Summary

The U.S. maintains a 6-12 month AI capability lead over China, but biotech IP theft is decimating American dominance—China now produces over one-third of new therapeutics compared to America's former monopoly. Lonsdale argues the real competitive advantage lies in accelerating FDA approval timelines (currently 700+ days vs. China's 90 days) and stopping patent system exploitation.

Key Takeaways

  1. China's biotech market share jumped from minimal to over 33% of new therapeutics in 7 years, with early-stage drugs hitting 50%+ in some categories—driven by IP theft, not pure competition.
  2. FDA approval bottleneck: Phase 1 trials take 700+ days in the U.S. versus 90 days in China and India, creating a structural disadvantage that makes U.S. biotech startups vulnerable to faster Chinese copies.
  3. Patent disclosure paradox: Patents actually educate adversaries rather than protect IP—China files copycat patents within 24 hours of seeing patent office filings, making the patent system counterproductive.
  4. Defense-in-depth over legal protection: Companies must invest in internal detection and cyber defenses to stop IP theft rather than relying on government enforcement or patent law, which have failed for decades.
  5. Portfolio example: Orca Bio's approval for safer bone marrow grafts (higher survival rates, autoimmune applications) shows how strong data can accelerate FDA timelines—but only if the investment isn't stolen before commercialization.

Related topics

Transcript Excerpt

I think you've said a number of times that you believe the U.S. is still leading in the eye race, but there are there are a number of factors to consider. Um, particularly on biotech as well, which we'll get to a little bit later, but take that and run with it. You know, your current attitude to this, this market, I mean, you're just talking about distillation. China for the last few decades has been very good at doing whatever they can to copy and steal our IP and our trade secrets. And this is no different. Right. And then unfortunately, we are I don't know if it's six months ahead or 12 months ahead or what it is. We are significantly ahead. And, you know, in a world where the agents are doubling capabilities every few months, that's a very, very large gap, which means we're way ahead i…

More from Bloomberg Technology